Glaxosmithkline Pharmaceuticals Ltd Share Price

Description

• GlaxoSmithKline Pharmaceuticals Ltd is in the Pharmaceuticals sector is having a market capitalization worth Rs. 25,676.02 crores, it is incorporated in the year 1924. It has reported consolidated sales of Rs. 789.99 crores in June 2021. The company is listed on the Bombay Stock Exchange (BSE) with the code 500660, and also listed on the National Stock Exchange (NSE) with the code GLAXO.

  GlaxoSmithKline Pharmaceuticals is one of the leading manufacturers of pharmaceuticals and vaccines in India. GSK entered the Indian market under the name of H J Foster & Co Ltd. The company generated 76% of its revenue from the selling and distribution of pharmaceuticals while the vaccine segment generated 24% of its revenue. 5 of the brands marketed by GSK feature in the India Pharmaceutical Market. These brands are (i) Augmentin, (ii) Betnovate, (iii) Calpol, (iv) Ceftum, and (v) Synflorix. GSK has a developed a team of over 5,000 employees spread across the country. GSK has also established two global Research & Development centers in the country. The promoters of the company own 75.0% of the stake in the company, Foreign Institutional Investors (FII) own 1.61% of the stake, Domestic Institutional Investors (DII) own 10.92%, and others (such as public & retail investors) hold the balance of 12.47%.

  In June 2021, quarterly net revenue was Rs. 773.46 crores, which has increased by approximately 19.24 % from Rs. 648.65 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 120.4 crores, which has improved sharply and increased by nearly 8.51% from a net profit of Rs. 110.96 crores in June 2020. In June 2021, the reported operating profit was at Rs. 645.05 crores, which is increased by 10.95% as compared to an operating profit of Rs. 581.39 crores for the quarter ending in June 2020. From an EPS of Rs. 6.55 in June 2020, the EPS of Glaxosmithkline Pharmaceuticals Ltd has improved and reached an EPS of Rs. 7.11 per share in June 2021. GLAXO's stock closed at Rs. 1,515.65 on 27th August’2021 (NSE). GlaxoSmithKline Pharmaceuticals Ltd has returned 3.77% in the last six months and returned 5.18% negatively in the previous year.

• GlaxoSmithKline Pharmaceuticals Ltd is in the Pharmaceuticals sector is having a market capitalization worth Rs. 25,676.02 crores, it is incorporated in the year 1924. It has reported consolidated sales of Rs. 789.99 crores in June 2021. The company is listed on the Bombay Stock Exchange (BSE) with the code 500660, and also listed on the National Stock Exchange (NSE) with the code GLAXO.

  GlaxoSmithKline Pharmaceuticals is one of the leading manufacturers of pharmaceuticals and vaccines in India. GSK entered the Indian market under the name of H J Foster & Co Ltd. The company generated 76% of its revenue from the selling and distribution of pharmaceuticals while the vaccine segment generated 24% of its revenue. 5 of the brands marketed by GSK feature in the India Pharmaceutical Market. These brands are (i) Augmentin, (ii) Betnovate, (iii) Calpol, (iv) Ceftum, and (v) Synflorix. GSK has a developed a team of over 5,000 employees spread across the country. GSK has also established two global Research & Development centers in the country. The promoters of the company own 75.0% of the stake in the company, Foreign Institutional Investors (FII) own 1.61% of the stake, Domestic Institutional Investors (DII) own 10.92%, and others (such as public & retail investors) hold the balance of 12.47%.

  In June 2021, quarterly net revenue was Rs. 773.46 crores, which has increased by approximately 19.24 % from Rs. 648.65 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 120.4 crores, which has improved sharply and increased by nearly 8.51% from a net profit of Rs. 110.96 crores in June 2020. In June 2021, the reported operating profit was at Rs. 645.05 crores, which is increased by 10.95% as compared to an operating profit of Rs. 581.39 crores for the quarter ending in June 2020. From an EPS of Rs. 6.55 in June 2020, the EPS of Glaxosmithkline Pharmaceuticals Ltd has improved and reached an EPS of Rs. 7.11 per share in June 2021. GLAXO's stock closed at Rs. 1,515.65 on 27th August’2021 (NSE). GlaxoSmithKline Pharmaceuticals Ltd has returned 3.77% in the last six months and returned 5.18% negatively in the previous year.